Potential COVID-19 vaccines have been announced by large pharmaceutical players. As we wait for the clinical trial to be over, we turn our attention to the next piece of the puzzle: transportation. Both Moderna and Pfizer’s vaccine requires that the doses remain cold. The future vaccine from Pfizer requires storage at -80C while Moderna is less demanding and requires -20 C for long-term shipping and storage, but remains stable for up to 30 days at 2 C to 8 C.

Large organisations such as The International Air Transport Association (IATA) already released guidelines to ensure that the air cargo industry is ready to support the large-scale handling, transportation and distribution of the future vaccine.

This is not the first time a vaccine requires to be this cold. Many types of vaccines must be transported via a cold supply chain. Industry leaders have even found ways to keep a vaccine between –60°C to –80°C in tropical places such as sub-Saharan Africa. But the scales at which these future vaccines will be distributed across the world has never been seen before.

Material handling industry leaders are now looking for outside-the-box solutions on how to store, transport and distribute a life-saving vaccine with unique cold storage requirements on a large scale.

Flutecorr combined with foam and other material may be used to provide that “last mile” delivery that will be crucial in this massive cold supply chain. We are working with key partners already in the industry to ramp up production if a need for our material becomes apparent. Contact our sales team if you think you can use Flutecorr for your out-of-the-box idea.